Back to search results

A Study of MBX 4291 for Adults with Obesity

This study is testing a new medication called MBX 4291 for adults with obesity. Researchers want to see how safe MBX 4291 is and how well your body tolerates it, compared to a placebo (an inactive substance). You might be able to join if you are 18 to 65 years old, have a Body Mass Index (BMI) between 30 and 50 kg/m2, and your weight has been stable for at least three months. The main goal is to track any side effects you might experience. This study plans to enroll about 124 participants, but its current recruitment status is unclear.

Study design
This is a Phase 1, double-blind study, meaning neither you nor your doctor will know if you are receiving MBX 4291 or a placebo. It will involve about 124 participants.
What's involved
MBX 4291 or placebo will be given as a shot under the skin (subcutaneously). Your total participation in the study, including screening and follow-up, could last up to 148 days.
Compensation
Not stated in the trial record.
Follow-up
You will be followed for up to 91 days in Part A, up to 99 days in Part B, and up to 148 days in Part C after starting the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07142707

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity

Recruiting
PHASE1Ages 18–65InterventionalTreatment
MBX Biosciences
~124 participants
Updated 2026-06-09 on ClinicalTrials.gov
What's tested:MBX 4291Placebo

At a glance

Recruiting sites
4 of 4 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of participants with Treatment Emergent Adverse Events (TEAEs)
Measured over The total duration of study participation for each participant including screening, treatment period, follow-up, and end of study visit will be up to 91 days in Part A, up to 99 days in Part B, and up to 148 days in Part C.

Conditions

Obesity

Explore related trials

Obesity

Where it's being run

4 sites across 4 states
Florida1
Kentucky1
Missouri1
Tennessee1

Who to contact

Elisa Fabbrini, MD, PhD
[email protected]
844-877-4473
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age of \>18 to ≤65 years at the time of signing the informed consent.
Has a BMI of ≥30 to \<50 kg/m2 at screening and baseline.
Weight-stable, i.e., no more than ±5% change in body weight for at least 3 months prior to screening and between screening and baseline.

Exclusion

History of, or currently active, significant illness or medical disorders that in the opinion of the investigator may preclude participants from participating in the study.
History of currently active pancreatitis, type I and type II diabetes.
Secondary causes of obesity, including but not limited to hypothalamic, monogenic, syndromic, or endocrine causes.
A personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

What this trial measures

  • Number of participants with Treatment Emergent Adverse Events (TEAEs)The total duration of study participation for each participant including screening, treatment period, follow-up, and end of study visit will be up to 91 days in Part A, up to 99 days in Part B, and up to 148 days in Part C.